The research for markers of therapeutic response could help us to individualize therapies in bladder cancer. In this work the authors studied a population of 71 patients submitted to neodjuvant chemotherapy and posterior radical cystectomy, and divided the on responders and non-responders based on final pathological report. By DNA-based technology, the authors concluded that ERBB2 mutations are a prognostic factor of good response to cisplatin base chemotherapy. Although this constitutes a very promising marker for selecting patients for NAC, further validation of their results is warranted in order to establish the reliability of their results.
